The Imagion Biosystems Annual Report for the year ended 31 December 2018 is available here. Download the 2018 Annual Report.
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
